Antibody-drug conjugate · Cytotoxic, directed at HER3 (ErbB3) (ERBB3) and DNA topoisomerase I (TOP1) · developed by BioNTech
Beruzatatug pelitecan is an antibody-drug conjugate made of an IgG1 antibody that binds HER3 (ErbB3) on tumor cells, linked by a protease-cleavable tripeptide linker to the topoisomerase I inhibitor YL0010014. After cleavage in the tumor microenvironment, the released payload stabilizes topoisomerase I-DNA cleavable complexes, causing DNA breaks and apoptosis. It is being studied in advanced solid tumors.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07070232 | Phase 1/2 | Advanced Solid Tumor | Recruiting | BNTX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Advanced Solid Tumor
See BNTX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
BNTX catalysts and pipeline →